

INFORMATION DISCLOSURE  
CITATION

PTO-1449

ATTY. DOCKET NO.  
A-67689-3/RFT/RMS/RMKSERIAL NO.  
09/653,924APPLICANT  
HORWITZ, David A.FILING DATE  
September 1, 2000GROUP  
1646

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

RECEIVED

JUL 23 2001

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
MH	51	99/25366	5/9/1999	WO			
MH	52	99/48524	9/30/99	WO			
MH	53	00/66158	11/9/00	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MH	54	ASAI O, et al., "Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation," <i>Journal of Clinical Investigation</i> 101(9):1835-1842 (1998)					
MH	55	ZEHAVI-WILLNER et al., "The Mitogenic Activity of Staphylococcal Enterotoxin B (SEB): A Monovalent T Cell Mitogen That Stimulates Cytolytic T Lymphocytes but Cannot Mediate Their Lytic Interaction," <i>Journal of Immunology</i> 127(8):2682-2687 (1986)					
MH	56	KOH et al., "Adoptive cellular immunotherapy: NK cells and bone marrow transplantation," <i>Histol Histopathol</i> 15:1201-1210 (2000)					
MH	57	ZELLER et al., "Induction of CD4+ T Cell Alloantigen-Specific Hyporesponsiveness by IL-10 and TGF- $\beta$ 1," <i>Journal of Immunology</i> 163:3684-3691 (1999)					
MH	58	BOUSSIOTIS, "Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor- $\beta$ -treated alloreactive T cells that do not induce graft-versus-host disease," <i>Blood</i> 97:565-571 (2001)					

EXAMINER Maher Haddad

DATE CONSIDERED 9/04/02

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	09/653,924
				Filing Date	September 1, 2000
				First Named Inventor	HORWITZ, David A.
				Group Art Unit	1644
				Examiner Name	HADDAD, Maher M.
				Attorney Docket Number	A-67689-3/RFT/RMS/RMK
Sheet	1	of	5		

[illegible][illegible]

Examiner Signature	Maher Haddad	Date Considered	9/04/02
-----------------------	--------------	--------------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Business Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/653,924
		Filing Date	September 1, 2000
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1644
Examiner Name	HADDAD, Maher M.		
Attorney Docket Number	A-67689-3/RFT/RMS/RMK		
Sheet	2	of	5



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	61	ASANO M, et al., "Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation." J Exp Med. 1996 Aug 1;184(2):387-96.	
	62	AUCHINCLOSS, Hugh Jr., et al, in Fundamental Immunology 4th Ed., Paul, W.E. (ed.) Lippincot-Raven: Philadelphia New York; 1999 pp. 1182-1222.	
	63	BETZ, M. and FOX, B.S., "Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines," J Immunol. 1991 Jan 1;146(1):108-13.	
	64	BONIG H, et al., "Transforming growth factor-beta1 suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes." Scand J Immunol. 1999 Dec;50(6):612-8.	
	65	BUCY, R.P. et al., FASEB J. 1995 9:A497 (Abstract)	
	66	CHANDRASEKAR, B., et al., "Dietary calorie restriction inhibits transforming growth factor-beta (TGF- beta) expression in murine lupus nephritis", 9th International Congress on Immunology, 848 (1995)	
	67	CHONG P. et al. "Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production," Autoimmunity, 10:227-231 (1991)	
	68	COSIMI, A.B., et al., "Treatment of acute renal allograft rejection with OKT3 monoclonal antibody," Transplantation. 1981 Dec;32(6):535-9.	
	69	DELGIUDICE, G., et al., "TGF-beta activity is increased in systemic lupus erythematosus (SLE) and progressive systemic sclerosis (PSS)", Arthritis and Rheumatism Vol. 36 (9 Suppl.) p S196(Sept. 1993)	
	70	DOOMS, H. et al., "IL-2 and IL-15 direct the outcome of inappropriate CD4+ T cell stimulation towards apoptosis and anergy respectively," European Cytokine Network, 9(3):169 (1998)	
	71	FERNANDES, G., et al., "Calorie restriction delays autoimmune murine lupus by differentially modulating oncogenes and TGF- beta-1 expression", 9th International Congress on Immunology., 848 (1995).	
	72	GAO Q, et al., "CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice." Transplantation. 1999 Dec 27;68(12):1891-7.	
	73	GRAY et al., "Activated Natural Killer Cells Can Induce Resting B Cells to Produce Immunoglobulin," Arthritis & Rheumatism, 37(9)suppl:S378 (1994)	
	74	GRAY, J. D., et al., "Generation of an Inhibitory Circuit Involving CD8+ T Cells, IL-2, and NK Cell-Derived TGF-β: Contrasting Effects of Anti-CD2 and Anti-CD3", Journal of Immunol., 160:2248-2254 (1998).	
	75	GROUX, H., et al., "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature. 1997 Oct 16;389(6652):737-42.	
	76	HAHN, B.H., Dubois' Lupus Erythematosus, 5th Ed. (1997), pp. 69-76 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	
	77	HORWITZ DA, et al., "Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus." Arthritis Rheum. 1998 May;41(5):838-44.	
	78	HORWITZ, D. A., et al., "The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity", Immunology Today, Vol. 18(11):538-542 (Nov. 1997).	
MM	79	HORWITZ, D.A., Dubois' Lupus Erythematosus, 5th Ed. (1997), pp. 155-194 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1089228\_1.DOC

RECEIVED

TECH CENTER 1600/2900

AUG 14 2002


Please type a plus sign (+) inside this box

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/653,924
		Filing Date	September 1, 2000
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1644
		Examiner Name	HADDAD, Maher M.
		Attorney Docket Number	A-67689-3/RFT/RMS/RMK
Sheet	3	of	5



RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mH	80	HUGGINS, M. L., et al., "Modulation of the Autoimmune Response in Lupus Mice by Oral Administration of Attenuated Salmonella typhimurium Expressing the IL-2 and TGF-β Genes", Annals of New York Acad. of Sciences, Vol. 815:499-502 (1997)	
	81	JACKSON AL, et al., "Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells." Clin Immunol Immunopathol. 1990 Jan;54(1):126-33.	
	82	JONULEIT, H., et al., "Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells," J Exp Med. 2000 Nov 6;192(9):1213-22.	
	83	KANEGANE H, et al., "A novel subpopulation of CD45RA+ CD4+ T cells expressing IL-2 receptor alpha-chain (CD25) and having a functionally transitional nature into memory cells." Int Immunol. 1991 Dec;3(12):1349-56.	
	84	KIRK, A.D., et al., "CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates," Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94.	
	85	KLINMAN DM, et al., "Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus." Arthritis Rheum. 1991 Nov;34(11):1404-10.	
	86	KOIDE, J. and ENGLEMAN, E.G., "Differences in surface phenotype and mechanism of action between alloantigen specific CD8+ cytotoxic and suppressor T cell clones," J Immunol. 1990 Jan 1;144(1):32-40.	
	87	LANCASTER, F., et al., "Anti-idiotypic T cells suppress rejection of renal allografts in rats," Nature. 1985 May 23-29;315(6017):336-7.	
	88	LANGREHR, J.M., et al., "Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL," Transplantation. 1992 Mar;53(3):632-40.	
	89	LARSEN, C.P., et al., "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways." Nature. 1996 May 30;381(6581):434-8.	
	90	LINKER-ISRAELI M, et al., "CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis." Arthritis Rheum. 1990 Aug;33(8):1216-25.	
	91	MASSAGUE J., "The transforming growth factor-beta family." Annu Rev Cell Biol. 1990;6:597-641.	
	92	MIZUOCHI, T., et al., "Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogeneic major histocompatibility antigens but not against trinitrophenyl-modified self," J Exp Med. 1985 Aug 1;162(2):427-43.	
	93	MYSLIWIEZ J and THIERFELDER S., "Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient." Blood. 1992 Nov 15;80(10):2661-7 (Abstract)	
	94	OHTSUKA, K., et al., "Decreased Production of TGF-β by Lymphocytes from Patients with Systemic Lupus Erythematosus", J. Immunol. 160:2539-2545 (1998).	
	95	PAPIERNIK M, et al., "T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity." J Immunol. 1997 May 15;158(10):4642-53.	
mH	96	PEARCE, N.W., et al., "Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. V. Dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2," Transplantation. 1993 Feb;55(2):374-80.	

Examiner Signature	Maher Haddad	Date Considered	09/04/02
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1089228\_1.DOC


Please type a plus sign (+) inside this box

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/653,924
		Filing Date	September 1, 2000
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1644
		Examiner Name	HADDAD, Maher M.
Sheet 4 of 5	Attorney Docket Number	A-67689-3/RFT/RMS/RMK	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mH	97	PESCOVITZ, M.D., et al., "Effect of class II antigen matching on renal allograft survival in miniature swine," J Exp Med. 1984 Nov 1;160(5):1495-508. QIN, L., et al., "Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1," Ann Surg. 1994 Oct;220(4):508-18; discussion 518-9.	
	98	POWRIE F, et al., "A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells." J Exp Med. 1996 Jun 1;183(6):2669-74.	
	99	QIN, L., et al., "Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1," Ann Surg. 1994 Oct;220(4):508-18; discussion 518-9	
	100	QIN, L., et al., "Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival," J Immunol. 1996 Mar 15;156(6):2316-23.	
	101	RAJU, G.P., et al., "Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats," Transplantation. 1994 Aug 15;58(3):392-6.	
	102	RAMSDALL, F. and FOWLKES, B.J., "Maintenance of in vivo tolerance by persistence of antigen," Science. 1992 Aug 21;257(5073):1130-4.	
	103	READ S, et al., "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation." J Exp Med. 2000 Jul 17;192(2):295-302.	
	104	ROCHA, B., et al., "Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen," J Exp Med. 1993 May 1;177(5):1517-21.	
	105	ROSER, B.J., "Cellular mechanisms in neonatal and adult tolerance," Immunol Rev. 1989 Feb;107:179-202.	
	106	SAKAGUCHI S, et al., "Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease." J Exp Med. 1985 Jan 1;161(1):72-87.	
	107	SAKAGUCHI, S., et al., "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases," J Immunol. 1995 Aug 1;155(3):1151-64.	
	108	SEDDON, B. and MASON, D., "The third function of the thymus," Immunol Today. 2000 Feb;21(2):95-9.	
	109	SHEVACH, E.M., "Regulatory T cells in autoimmunity," Annu Rev Immunol. 2000;18:423-49.	
	110	SHIVAKUMAR S, et al., "T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis." J Immunol. 1989 Jul 1;143(1):103-12.	
	111	SINGER, A., et al., "Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells," J Exp Med. 1981 May 1;153(5):1286-301.	
	112	SNIJDEWINT, F.G., et al., "Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes," J Immunol. 1993 Jun 15;150(12):5321-9.	
mH	113	STARZL, T.E., et al., "Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation," Transplantation. 1993 Jun;55(6):1272-7.	

TECH CENTER 1600/2500  
AUG 14 2002

RECEIVED

Examiner Signature	Maher Haddad	Date Considered	09/04/02
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐


PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/653,924
		Filing Date	September 1, 2000
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1644
		Examiner Name	HADDAD, Maher M.
Sheet	5	of	5
		Attorney Docket Number	A-67689-3/RFT/RMS/RMK



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mt	114	STRAND, V., "Approaches to the management of systemic lupus erythematosus," Current Opinion in Rheumatology, 9:410-420 (1997)	
	115	SURI-PAYER E, et al., "CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells." J Immunol. 1998 Feb 1;160(3):1212-8.	
	116	SURI-PAYER E, et al., "Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells." Eur J Immunol. 1999 Feb;29(2):669-77.	
	117	TAAMS, L.S., et al., "Anergic T cells actively suppress T cell responses via the antigen-presenting cell," Eur J Immunol. 1998 Sep;28(9):2902-12.	
	118	TAKAHASHI T, et al., "Human CD8+ lymphocytes stimulated in the absence of CD4+ cells enhance IgG production by antibody-secreting B cells." Clin Immunol Immunopathol. 1991 Mar;58(3):352-65.	
	119	TAKAHASHI T, et al., "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state." Int Immunol. 1998 Dec;10(12):1969-80.	
	120	THORNTON AM and SHEVACH EM. "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production." J Exp Med. 1998 Jul 20;188(2):287-96.	
	121	THORNTON AM and SHEVACH EM. "Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific." J Immunol. 2000 Jan 1;164(1):183-90.	
	122	TOMITA, Y., et al., "Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?" J Immunol. 1990 Jan 15;144(2):463-73.	
	123	VENDETTI, S., et al., "Anergic T cells inhibit the antigen-presenting function of dendritic cells," J Immunol. 2000 Aug 1;165(3):1175-81.	
	124	VERBANAC, K.M., et al., "A role for transforming growth factor-beta in the veto mechanism in transplant tolerance. Transplantation. 1994 Mar 27;57(6):893-900.	
	125	WAHL SM. "Transforming growth factor beta: the good, the bad, and the ugly." J Exp Med. 1994 Nov 1;180(5):1587-90.	
	126	WEKERLE, T., et al., "Anti-CD154 or CTLA4lg obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance," Transplantation. 1999 Nov 15;68(9):1348-55.	
	127	WEINER HL, et al., "Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens." Annu Rev Immunol. 1994;12:809-37	
	128	WILSON, D.B., "Idiotypic regulation of T cells in graft-versus-host disease and autoimmunity," Immunol Rev. 1989 Feb;107:159-77.	
	129	ZHENG, X.X., et al., "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," J Immunol. 1995 May 15;154(10):5590-600.	
mt	130	MARTIN, P.J. et al., "Treatment of Acute Graft-Versus-Host Disease with Anti-CD3 Monoclonal Antibodies," Am Jour Kidney Disease 11(2):149-152 (1988)	

Examiner Signature	Maher Haddad	Date Considered	09/04/02
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 Unique citation designation number. \* Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.  
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
 1089228\_1.DOC

RECEIVED

AUG 14 2002  
 1600/2900





<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449		ATTY. DOCKET NO. A-67689-3/RFT/RMS/RMK	SERIAL NO. 09/653,924
		APPLICANT HORWITZ	
		FILING DATE September 1, 2000	GROUP Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
mk	7.	Vallera et al., "Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone", <i>Transplantation</i> 31:218-222 (1981)	
	8.	Martin et al., "Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts", <i>Blood</i> 66:664-672 (1985)	
	9.	Patterson et al., "Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation", <i>Br J Haematol</i> 63:221-230 (1986)	
	10.	Goldman et al., "Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion", <i>Ann Intern Med</i> 108:806-814 (1988)	
	11.	Lucas et al., "The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation", <i>Blood</i> 87:2594-2603 (1996)	
	12.	Blazar et al., "FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation", <i>J. Immunol</i> 153:1836-1846 (1994)	
	13.	Blazar et al., "Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome", <i>J. Immunol</i> 151:5726-5741 (1993)	
	14.	Dumont et al., "Distinct Mechanisms of Suppression of Murine T Cell Activation by the Related macrolides FK-506 and Rapamycin", <i>J. Immunol</i> 144:251-258 (1990)	
	15.	Morris, "Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action", <i>Ann NY Acad Sci</i> 685:68-72 (1993)	
	16.	Gratama et al., "Treatment of Acute Graft-Versus-Host Disease With Monoclonal Antibody OKT3. Clinical results and effect on circulating T lymphocytes", <i>Transplantation</i> 38(5):469-474 (1984)	
	17.	Hiruma et al., "Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space", <i>Blood</i> 79:3050-3058 (1992)	
	18.	Anasetti et al., "Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody", <i>Transplantation</i> 54:844-851 (1992)	
	19.	Martin et al., "Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease", <i>Bone Marrow Transplant</i> 3:437-444 (1989)	
	20.	Herve et al., "Treatment of Corticosteroid Resistant Acute Graft-Versus-Host Disease by In Vivo Administration of Anti-Interleukin-2 Receptor Monoclonal Antibody (B-B10)", <i>Blood</i> 75(4):1017-1023 (1990)	
	21.	Boussiotis et al., "B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance", <i>J Exp Med</i> 178:1753-1763 (1993)	
	22.	Gribben et al., "Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool", <i>Blood</i> 97:4887-4893 (1996)	
	23.	Blazar et al., "Recent advances in graft-versus-host disease (GVHD)", <i>Immunol Rev</i> 157:79-90 (1997)	
mk	24.	Krenger et al., "Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens", <i>Transplantation</i> 58:1251-1257 (1994)	
EXAMINER		DATE CONSIDERED	
Maher Haddad		9/16/00	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# INFORMATION DISCLOSURE CITATION

PTO-1449

JAN 16 2001

ATTY. DOCKET NO.  
A-67689-3/RFT/RMS/RMKSERIAL NO.  
09/653,924APPLICANT  
HORWITZFILING DATE  
September 1, 2000GROUP  
Not Yet Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

mh	25.	Blazar et al., "Both CD4+ and CD8+ T Cells Can Cause Accelerated GVHD Lethality in the Presence of High In Vivo Doses of Exogenous Ill10: Role of Interferon Gamma (IFN $\gamma$ ) in GVHD Induction, <i>Blood</i> 88:247 (1996) (abstract)
	26.	Krenger et al., "Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease", <i>J Immunol</i> 153:585-593 (1995)
	27.	Fowler et al., "Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice", <i>Blood</i> 84:3540-3549 (1994)
	28.	Bonini et al., "HSY-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, <i>Science</i> 276:1719-1724 (1997)
	29.	Storb et al., "Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia", <i>Blood</i> 80:560-561 (1992)
	30.	Sullivan et al., "Chronic Graft-Versus-Host Disease and Other Late Complications of Bone Marrow Transplantation", <i>Semin Hematol</i> 28:250-259 (1992)
	31.	Via et al., "Critical Role of interleukin-2 in the development of acute graft-versus-host disease", <i>International Immunol</i> 5:565-572 (1993)
	32.	Fast, "Generation and characterization of IL-2-activated veto cells", <i>J Immunol</i> 149:1510-1515 (1992)
	33.	Hirohata et al., "Role of IL-2 in the generation of CD4+ suppressors of human B cell responsiveness", <i>J Immunol</i> 142:3104-3112 (1989)
	34.	Taylor, "Antigen specific suppressor T cells respond to cytokines released by T cells", <i>Advances Exp Med Biol</i> 319:125-135 (1992)
	35.	Kinter et al., "Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression", <i>Proc. Natl. Acad. Sci. USA</i> 92:10985-10989 (1995)
	36.	Barker et al., "Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation," <i>J Immunol</i> 156:4476-4483 (1996)
	37.	Hirokawa et al., "Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation", <i>J. Immunol.</i> 149:1859-1866, 1992
	38.	Border et al., "Transforming growth factor-beta in disease: the dark side of tissue repair," <i>J Clin Invest</i> 90:1-7 (1992)
	39.	Sporn et al., "Some recent advances in the chemistry and biology of transforming growth factor-beta," <i>J Cell Biol</i> 105:1039-1045 (1987)
	40.	Massague, "Receptors for the TGF-beta family", <i>Cell</i> 69:1067-1070 (1992)
	41.	Murphy et al, "The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation," <i>Immunol Rev</i> 157:167-176 (1997)
mh	42.	Chavin, et al., "Anti-CD2 mAbs Suppress Cytotoxic Lymphocyte Activity by the Generation of Th2 Suppressor Cells and Receptor Blockade," <i>J Immunol</i> 152:3729-3739 (1994)

EXAMINER

Maken Haddad

DATE CONSIDERED

9/16/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<div>INFORMATION DISCLOSURE CITATION</div> <div>PTO-1449</div> <div><div>PATENT OFFICE 607</div><div>JAN 16 2001</div></div>		ATTY. DOCKET NO. A-67689-3/RFT/RMS/RMK		SERIAL NO. 09/653,924	
		APPLICANT HORWITZ			
		FILING DATE September 1, 2000		GROUP Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
mt	43.	Pawelec, et al., "Cytokine Modulation of TH1/TH2 Phenotype Differentiation in Directly Alloresponsive CD4+ Human T Cells," <i>Transplantation</i> 62(8):1095-1101 (1996)			
	44.	Halverson, et al., "In Vitro Generation of Allospecific Human CD8+ T Cells of Tc1 and Tc2 Phenotype," <i>Blood</i> 90(5):2089-2096 (1997)			
	45.	Zeller, et al., "Ex vivo IL10 and TGF-Beta Act Synergistically to Induce CD4+ Alloantigen-Specific Tolerance Resulting in Diminished Graft-Versus-Host Disease in Vivo," <i>FASEB Journal</i> (March 12, 1999) 12(4)part 1, A614. Meeting Info: Annual Meeting of the Professional Research Scientists for Experimental Biology. April 17-21 1999.			
	46.	Oswald, et al., "IL-10 Synergizes with IL-4 and Transforming Growth Factor-Beta to Inhibit macrophage Cytotoxic Activity," <i>J Immunology</i> 148(11):3578-3582 (1992)			
	47.	Han, et al., "A New Type of CD4+ Suppressor T cell Completely Prevents Spontaneous Autoimmune Diabetes and Recurrent Diabetes in Syngeneic Islet-Transplanted NOD Mice," <i>Journal of Autoimmunity</i> , 9:331-339 (1996)			
	48.	Rook et al., "Effects of Transforming Growth Factor $\beta$ on the Functions of Natural Killer Cells: Depressed Cytolytic Activity and Blunting of Interferon Responsiveness," <i>J Immunology</i> 136(10):3916-3920 (1986)			
	49.	Gray et al., "Generation of an Inhibitory Circuit Involving CD8+ T Cells, IL-2 and NK Cell-Derived TGF- $\beta$ : Contrasting Effects of Anti-CD2 and Anti-CD3", <i>J Immunol</i> , 160:2248-2254 (1998)			
mt	50	Gray et al., "The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells", <i>J Exp Med</i> 180:1937-1942 (1994)			
EXAMINER		DATE CONSIDERED			
Maken Haddad		9/16/02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.